Lymphadenectomy promotes tumor growth and cancer cell dissemination in the spontaneous RET mouse model of human uveal melanoma

Oncotarget

Volumn 6, Issue 42, 2015, Pages 44806-44818

  Pin, Yeo Kim ^a   Khoo, Karen ^b   Tham, Muly ^b   Karwai, Tan ^b,c   Hwee, Thiam Chung ^a   Puaux, Anne Laure ^b   Phua, Meow Ling Cindy ^b   Kato, Masashi ^d   Angeli, Veronique ^a   Abastado, Jean Pierre ^b,e  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b AGENCY FOR SCIENCE   (Singapore)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e IRIS Institut de Recherches Internationales Servier   (France)

Author keywords

Inflammation; Lymphadenectomy; Uveal melanoma

Indexed keywords

CELECOXIB; DEXAMETHASONE PLUS TOBRAMYCIN; PROTEIN KINASE B; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; CYCLOOXYGENASE 2 INHIBITOR; PROTEIN RET; RET PROTEIN, HUMAN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; LYMPH NODE DISSECTION; LYMPHANGIOGENESIS; MALE; METASTASIS; MOUSE; MOUSE MODEL; NONHUMAN; ONCOLOGICAL PARAMETERS; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR HOMEOSTASIS; TUMOR MICROENVIRONMENT; UVEA MELANOMA; ADVERSE EFFECTS; ANIMAL; CELL MOTION; CELL PROLIFERATION; DISEASE COURSE; DRUG EFFECTS; GENETIC PREDISPOSITION; GENETICS; HUMAN; MELANOMA; METABOLISM; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHENOTYPE; PHOSPHORYLATION; SECONDARY; TIME FACTOR; TRANSGENIC MOUSE; TUMOR VOLUME; UVEAL NEOPLASMS;

ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; CYCLOOXYGENASE 2 INHIBITORS; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LYMPH NODE EXCISION; MALE; MELANOMA; MICE; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-RET; TIME FACTORS; TUMOR BURDEN; UVEAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84953433006     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6326     Document Type: Article

References (67)

1. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331:1565-1570.
2. Angeli V, Randolph GJ. Inflammation, lymphatic function, and dendritic cell migration. Lymphat Res Biol. 2006; 4:217-228.
3. Lim HY, Thiam CH, Yeo KP, Bisoendial R, Hii CS, McGrath KC, Tan KW, Heather A, Alexander JS, Angeli V. Lymphatic vessels are essential for the removal of cholesterol from peripheral tissues by SR-BI-mediated transport of HDL. Cell Metab. 2013; 17:671-684.
4. Wong JH, Cagle LA, Morton DL. Lymphatic drainage of skin to a sentinel lymph node in a feline model. Ann Surg. 1991; 214:637-641.
5. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, Foshag LJ, Cochran AJ. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surgery. 1992; 127:392-399.
6. Sleeman J, Schmid A, Thiele W. Tumor lymphatics. Semin Cancer Biol. 2009; 19:285-297.
7. Tanis PJ, Nieweg OE, Valdes Olmos RA, Th Rutgers EJ, Kroon BB. History of sentinel node and validation of the technique. Breast cancer research: BCR. 2001; 3:109-112.
8. Veronesi U, Adamus J, Bandiera DC, Brennhovd O, Caceres E, Cascinelli N, Claudio F, Ikonopisov RL, Javorski VV, Kirov S, Kulakowski A, Lacour J, Lejeune F, Mechl Z, Morabito A, Rode I, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer. 1982; 49:2420-2430.
9. Sim FH, Taylor WF, Pritchard DJ, Soule EH. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clinic Proceedings. 1986; 61:697-705.
10. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Reintgen DS, Coventry BJ, Glass EC, Wang HJ. Sentinel-node biopsy or nodal observation in melanoma. N EnglJ Med. 2006; 355:1307-1317.
11. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet. 1998; 351:793-796.
12. Bamboat ZM, Konstantinidis IT, Kuk D, Ariyan CE, Brady MS, Coit DG. Observation after a positive sentinel lymph node biopsy in patients with melanoma. Ann Surg Oncol. 2014; 21:3117-3123.
13. Balch CM, Soong SJ, Bartolucci AA, Urist MM, Karakousis CP, Smith TJ, Temple WJ, Ross MI, Jewell WR, Mihm MC, Barnhill RL, Wanebo HJ. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg. 1996; 224:255-263; discussion 263-256.
14. Kato M, Takahashi M, Akhand AA, Liu W, Dai Y, Shimizu S, Iwamoto T, Suzuki H, Nakashima I. Transgenic mouse model for skin malignant melanoma. Oncogene. 1998; 17:1885-1888.
15. Lengagne R, Graff-Dubois S, Garcette M, Renia L, Kato M, Guillet JG, Engelhard VH, Avril MF, Abastado JP, Prevost-Blondel A. Distinct role for CD8 T cells toward cutaneous tumors and visceral metastases. J Immunol. 2008; 180:130-137.
16. Eyles J, Puaux AL, Wang X, Toh B, Prakash C, Hong M, Tan TG, Zheng L, Ong LC, Jin Y, Kato M, Prevost-Blondel A, Chow P, Yang H, Abastado JP. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest. 2010; 120:2030-2039.
17. Ardjomand N, Komericki P, Langmann G, Mattes D, Moray M, Scarpatetti M, El-Shabrawi Y. Lymph node metastases arising from uveal melanoma. Wiener klinische Wochenschrift. 2005; 117:433-435.
18. Harris MS, Harris GJ, Simons KB, Campbell BH. Massive extraocular extension and parotid lymph node metastasis of uveal melanoma. Ophthal Plast Reconstr Surg. 2007; 23:430-432.
19. Dithmar S, Diaz CE, Grossniklaus HE. Intraocular melanoma spread to regional lymph nodes: report of two cases. Retina. 2000; 20:76-79.
20. Boonman ZF, van Mierlo GJ, Fransen MF, Franken KL, Offringa R, Melief CJ, Jager MJ, Toes RE. Intraocular tumor antigen drains specifically to submandibular lymph nodes, resulting in an abortive cytotoxic T cell reaction. J Immunol. 2004; 172:1567-1574.
21. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002; 29(6 Suppl 16):15-18.
22. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001; 357:539-545.
23. Montalto E, Mangraviti S, Costa G, Carrega P, Morandi B, Pezzino G, Bonaccorsi I, Cancellieri A, Mingari MC, Mesiti M, Ferlazzo G, Melioli G. Seroma fluid subsequent to axillary lymph node dissection for breast cancer derives from an accumulation of afferent lymph. Immunol Lett. 2010; 131:67-72.
24. Tammela T, Saaristo A, Holopainen T, Lyytikka J, Kotronen A, Pitkonen M, Abo-Ramadan U, Yla-Herttuala S, Petrova TV, Alitalo K. Therapeutic differentiation and maturation of lymphatic vessels after lymph node dissection and transplantation. Nat Med. 2007; 13:1458-1466.
25. Notivol R, Amin D, Whitling A, Wells D, Kennedy M, Cockrum PC. Prophylactic effectiveness of tobramycin-dexamethasone eye drops compared with tobramycin/vehicle eye drops in controlling post-surgical inflammation in cataract patients: prospective, randomised, double-masked, two-arm, parallel-group, placebo-controlled, multicentre study. Clin Drug Investig. 2004; 24:523-533.
26. Gurpinar E, Grizzle WE, Piazza GA. COX-Independent Mechanisms of Cancer Chemoprevention by Anti-Inflammatory Drugs. Front Oncol. 2013; 3:181.
27. Toh B, Wang X, Keeble J, Sim WJ, Khoo K, Wong WC, Kato M, Prevost-Blondel A, Thiery JP, Abastado JP. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLOS Biology. 2011; 9:e1001162.
28. Madhunapantula SV, Robertson GP. The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res. 2009; 22:400-419.
29. Madhunapantula SV, Mosca PJ, Robertson GP. The Akt signaling pathway: an emerging therapeutic target in malignant melanoma. Cancer Biology & Therapy. 2011; 12:1032-1049.
30. Inamdar GS, Madhunapantula SV, Robertson GP. Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol. 2010; 80:624-637.
31. Becker MR, Siegelin MD, Rompel R, Enk AH, Gaiser T. COX-2 expression in malignant melanoma: a novel prognostic marker? Melanoma Res. 2009; 19:8-16.
32. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate. 2000; 42:73-78.
33. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, Koki AT. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer. 2000; 89:2637-2645.
34. Qiu X, Cheng JC, Chang HM, Leung PC. COX2 and PGE2 mediate EGF-induced E-cadherin-independent human ovarian cancer cell invasion. Endocrine-Related Cancer. 2014; 21:533-543.
35. Jendrossek V. Targeting apoptosis pathways by Celecoxib in cancer. Cancer Lett. 2013; 332:313-324.
36. Cady B. Lymph node metastases. Indicators, but not governors of survival. Arch Surg. 1984; 119:1067-1072.
37. Sleeman JP, Cremers N. New concepts in breast cancer metastasis: tumor initiating cells and the microenvironment. Clin Exp Metastasis. 2007; 24:707-715.
38. Sceneay J, Smyth MJ, Moller A. The pre-metastatic niche: finding common ground. Cancer Metastasis Rev. 2013; 32:449-464.
39. Tan KW, Yeo KP, Wong FH, Lim HY, Khoo KL, Abastado JP, Angeli V. Expansion of cortical and medullary sinuses restrains lymph node hypertrophy during prolonged inflammation. J Immunol. 2012; 188:4065-4080.
40. Huggenberger R, Ullmann S, Proulx ST, Pytowski B, Alitalo K, Detmar M. Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation. J Exp Med. 2010; 207:2255-69.
41. Szuba A, Skobe M, Karkkainen MJ, Shin WS, Beynet DP, Rockson NB, Dakhil N, Spilman S, Goris ML, Strauss HW, Quertermous T, Alitalo K, Rockson SG. Therapeutic lymphangiogenesis with human recombinant VEGF-C. FASEB J. 2002; 16:1985-7.
42. Huggenberger R, Siddiqui SS, Brander D, Ullmann S, Zimmermann K, Antsiferova M, Werner S, Alitalo K, Detmar M. An important role of lymphatic vessel activation in limiting acute inflammation. Blood. 2011; 117:4667-4678.
43. Fuller J, Guderian D, Kohler C, Schneider A, Wendt TG. Lymph edema of the lower extremities after lymphadenectomy and radiotherapy for cervical cancer. Strahlentherapie und Onkologie. 2008; 184:206-211.
44. Hardin RE, Lange JR. Surgical treatment of melanoma patients with early sentinel node involvement. Curr Treat Options Oncol. 2012; 13:318-326.
45. Shada AL, Walters DM, Tierney SN, Slingluff CL, Jr. Surgical resection for bulky or recurrent axillary metastatic melanoma. J Surg Oncol. 2012; 105:21-25.
46. Swantek JL, Cobb MH, Geppert TD. Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-alpha) translation: glucocorticoids inhibit TNF-alpha translation by blocking JNK/SAPK. Mol Cell Biol. 1997; 17:6274-6282.
47. Lee SW, Tsou AP, Chan H, Thomas J, Petrie K, Eugui EM, Allison AC. Glucocorticoids selectively inhibit the transcription of the interleukin 1 beta gene and decrease the stability of interleukin 1 beta mRNA. Proc Natl Acad Sci U S A. 1988; 85:1204-1208.
48. Abraham SM, Lawrence T, Kleiman A, Warden P, Medghalchi M, Tuckermann J, Saklatvala J, Clark AR. Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J Exp Med. 2006; 203:1883-1889.
49. Crofford LJ, Wilder RL, Ristimaki AP, Sano H, Remmers EF, Epps HR, Hla T. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. J Clin Invest. 1994; 93:1095-1101.
50. Kunz D, Walker G, Eberhardt W, Pfeilschifter J. Molecular mechanisms of dexamethasone inhibition of nitric oxide synthase expression in interleukin 1 beta-stimulated mesangial cells: evidence for the involvement of transcriptional and posttranscriptional regulation. Proc Natl Acad Sci U S A. 1996; 93:255-259.
51. Grosch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst. 2006; 98:736-747.
52. Ninomiya I, Nagai N, Oyama K, Hayashi H, Tajima H, Kitagawa H, Fushida S, Fujimura T, Ohta T. Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum. Oncol Rep. 2012; 28:777-784.
53. Retsky MW, Demicheli R, Hrushesky WJ, Baum M, Gukas ID. Dormancy and surgery-driven escape from dormancy help explain some clinical features of breast cancer. APMIS. 2008; 116(7-8):730-741.
54. Retsky M, Rogers R, Demicheli R, Hrushesky WJ, Gukas I, Vaidya JS, Baum M, Forget P, Dekock M, Pachmann K. NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup. Breast Cancer Res Treat. 2012; 134:881-888.
55. Demicheli R, Retsky MW, Hrushesky WJ, Baum M, Gukas ID. The effects of surgery on tumor growth: a century of investigations. Annals of Oncology. 2008; 19:1821-1828.
56. Weckermann D, Polzer B, Ragg T, Blana A, Schlimok G, Arnholdt H, Bertz S, Harzmann R, Klein CA. Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol. 2009; 27:1549-1556.
57. Tsunemi T, Nagoya S, Kaya M, Kawaguchi S, Wada T, Yamashita T, Ishii S. Postoperative progression of pulmonary metastasis in osteosarcoma. Clin Orthop Relat Res. 2003; :159-166.
58. Retsky M, Demicheli R, Hrushesky W, Baum M, Gukas I. Surgery triggers outgrowth of latent distant disease in breast cancer: an inconvenient truth? Cancers. 2010; 2:305-337.
59. Gottschalk A, Sharma S, Ford J, Durieux ME, Tiouririne M. Review article: the role of the perioperative period in recurrence after cancer surgery. Anesth Analg. 2010; 110:1636-1643.
60. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994; 79:315-328.
61. Hofer SO, Shrayer D, Reichner JS, Hoekstra HJ, Wanebo HJ. Wound-induced tumor progression: a probable role in recurrence after tumor resection. Arch Surg. 1998; 133:383-389.
62. Abramovitch R, Marikovsky M, Meir G, Neeman M. Stimulation of tumour growth by wound-derived growth factors. B J Cancer. 1999; 79:1392-1398.
63. O'Leary DP, Wang JH, Cotter TG, Redmond HP. Less stress, more success? Oncological implications of surgery-induced oxidative stress. Gut. 2013; 62:461-470.
64. Paraskeva PA, Ridgway PF, Olsen S, Isacke C, Peck DH, Darzi AW. A surgically induced hypoxic environment causes changes in the metastatic behaviour of tumours in vitro. Clin Exp Metastasis. 2006; 23:149-157.
65. Tham M, Khoo K, Yeo KP, Kato M, Prevost-Blondel A, Angeli V, Abastado JP. Macrophage depletion reduces postsurgical tumor recurrence and metastatic growth in a spontaneous murine model of melanoma. Oncotarget. 2015;6:22857-68. doi: 10.18632/oncotarget.3127.
66. Tsuchiya Y, Sawada S, Yoshioka I, Ohashi Y, Matsuo M, Harimaya Y, Tsukada K, Saiki I. Increased surgical stress promotes tumor metastasis. Surg. 2003; 133:547-555.
67. Forget P, Vandenhende J, Berliere M, Machiels JP, Nussbaum B, Legrand C and De Kock M. Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis. Anesth Analg. 2010; 110:1630-1635.